NEW YORK(GenomeWeb) – Signal Genetics said on Friday that its third quarter revenues increased 32 percent year over year. 

For the three months ended Sept. 30, the Carlsbad, Calif.-based cancer diagnostics firm said that revenues rose to $1.3 million from $983,589 in the year-ago quarter. 

"During the third quarter, we continued to execute on our business strategy by significantly growing our revenue, extending a key partnership and expanding our leadership team," Signal President and CEO Samuel Riccitelli said in a statement. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.